Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Halometasone→

Halometasone Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
50629-82-8
Molecular formula
C22H27ClF2O5
Molecular weight
444.9 g/mol
Drug class
Topical glucocorticoid corticosteroid
Mechanism of action
Activates intracellular glucocorticoid receptors in skin cells, regulating transcription of inflammatory mediators and suppressing local immune and inflammatory responses. This reduces erythema, oedema and pruritus in corticosteroid-responsive dermatoses.
Indications / reported uses
  • Topical treatment of inflammatory and pruritic corticosteroid-responsive dermatoses, including eczema and dermatitis, according to the product label and local authorisation.

Sources: https://pubchem.ncbi.nlm.nih.gov/#query=halometasone · https://www.ncbi.nlm.nih.gov/mesh/?term=halometasone · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Halometasone Environmental Risk Assessment (ERA) (the Halometasone ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.